Clinical Trial Update: Extension Study for the Port Delivery System With Ranibizumab (Portal) [Phase 3]

View source ↗

Summary

A Phase 3 extension study for the Port Delivery System with ranibizumab in neovascular age-related macular degeneration is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Port Delivery System with ranibizumab (ranibizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neovascular Age-Related Macular Degeneration | Phase 3 | Status: RECRUITING